HELP — CYBIN INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1833141 ·
Last close
$6.87
Market Cap
$425.83M
52W High
$7.06
52W Low
$3.76
ADV30
1,161,261
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -47,859,000 | -46,995,000 | 251,166,000 | 157,258,000 | 19,377,000 |
| Dec 2025 | 0 | — | -41,210,000 | -42,668,000 | 290,112,000 | 195,128,000 | 16,178,000 |
| Sep 2025 | 0 | — | -28,894,000 | -33,722,000 | 181,246,000 | 83,752,000 | 42,250,000 |
| Jun 2025 | 0 | — | -24,624,000 | -24,613,000 | 210,813,000 | 118,692,000 | 59,053,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-117,093,000
Investing CF
$-2,124,000
Financing CF
$219,389,000
CapEx
$-2,134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-342,540,000
Inventory
—
Receivables
$4,766,000
ST Investments
—
EBIT TTM
$-128,000,000
Pretax Income TTM
$-131,582,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -142,587,000 | -147,998,000 | 251,166,000 | 19,377,000 | — | -133,271,000 |
| Mar 2025 | 0 | -143,147,000 | -113,137,000 | 258,618,000 | 21,418,000 | — | -101,300,000 |
| Mar 2024 | 0 | -78,836,000 | -78,080,000 | 302,023,000 | 10,096,000 | — | -68,908,000 |
| Mar 2023 | 0 | -51,518,000 | -47,490,000 | 53,897,000 | 5,663,000 | — | -47,431,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RCKT | ROCKET PHARMACEUTICALS, INC. | $426.95M | $3.91 | — |
| SLN | Silence Therapeutics plc | $429.36M | $9.09 | — |
| EOLS | Evolus, Inc. | $435.30M | $6.61 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $436.38M | $6.68 | — |
| EBS | Emergent BioSolutions Inc. | $415.35M | $8.05 | — |
News headlines (Yahoo Finance, 1h cache)
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-07-06 19:53 · Yahoo
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
2026-06-29 11:40 · Yahoo
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?
2026-06-26 22:09 · Yahoo
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
2026-06-25 13:27 · Yahoo
Helus Pharma™ Announces US$50 Million Underwritten Offering
2026-06-24 10:01 · Yahoo
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
2026-06-24 10:00 · Yahoo
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
2026-06-22 12:00 · Yahoo
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
2026-06-11 11:30 · Yahoo
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
2026-06-01 11:30 · Yahoo
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.